- Blockade of IL-23: What is in the Pipeline? - Oxford Academic
Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents
- Risankizumab - Richtlijn - Richtlijnendatabase
De beslissing om de behandeling met risankizumab vóór de operatie te onderbreken, moet gebaseerd zijn op individuele factoren, zoals type en risico van chirurgische ingreep, patiëntkenmerken, individueel infectierisico enzovoort
- Landscape of anti-IL-23 therapy in inflammatory bowel disease: recent . . .
Risankizumab, mirikizumab and guselkumab are monoclonal antibodies that selectively target the IL-23p19 subunit and offer a novel mechanism of action This narrative review summarises key efficacy and safety data from the clinical trial programmes, highlights practical implications for their use in IBD, and reviews available data regarding
- ECCO Guidelines - ECCO - European Crohn’s and Colitis Organisation
Since the initiation of the first project in 2006, the ECCO Guidelines have become standard references for IBD management in Europe and around the world The guidelines are freely accessible and available for download on the ECCO Website and on JCC Online
- The rise and market race of anti-IL23p19 therapies in IBD: How ECCO . . .
With the recent approvals of all three major anti-IL-23p19 assets in at least one of the IBD indications, ECCO 2025 will provide critical insights into their future market trajectories
- Mirikizumab - Horizonscan geneesmiddelen
Version 3 (3 June 2025) Version 2 (3 December 2024) Version 1 (4 June 2024) Expand all sections
- Improving efficacy with longer mirikizumab treatment in CD
Vermeire S, et al Long-term efficacy and safety of mirikizumab treatment for Crohn’s disease: results from the VIVID-2 open-label extension study DOP05, 20th Congress of ECCO, 19–22 February 2025, Berlin, Germany
- P1039 An Evaluation of Anti-IL23 Therapy in Primary Sclerosing . . .
We conducted a multi-centre study, evaluating treatment experiences with Ustekinumab (a dual anti-IL12 23 agent), Risankizumab, and Mirikizumab (anti-IL23 alone)
|